Scientists discover new gatekeeper cell in the brain

Ghent, 12 February 2026 – VIB and Ghent University researchers have identified and characterized a previously unknown cellular barrier in the brain, which sheds new light on how the brain is protected from the rest of the body. In a study published in Nature Neuroscience, the scientists also reveal a new pathway by which the immune system can impact the brain.

Prof. Roosmarijn Vandenbroucke (VIB–UGent Center for Inflammation Research): “These findings reveal how vulnerable and protectable the brain is, opening new perspectives for more targeted interventions in brain disorders.”

The brain is protected from the rest of the body by multiple barriers that maintain a stable, tightly regulated environment and defend it against harmful substances and pathogens. The most well-known of these barriers is the blood-brain barrier but another critical interface is the choroid plexus, a small structure found within the brain's fluid-filled spaces, which produces cerebrospinal fluid. However, despite its importance, scientists know surprisingly little about the choroid plexus’ detailed cellular structure and how it protects the brain.

A new line of defense for the brain

Researchers from the Vandenbroucke lab at the VIB-UGent Center for Inflammation Research set out to unravel this puzzle. Using advanced gene sequencing techniques and high-resolution microscopy, the research team identified a unique population of cells located at the base of the choroid plexus that they coined the base barrier cells. These cells are linked together by tight junctions, molecular rivets that effectively form a seal. This barrier provides a functional compartmentalization of the choroid plexus, the brain, and the cerebrospinal fluid.

Base barrier cells (pink)
“We’ve uncovered a new line of defense for the brain,” explains Prof. Vandenbroucke (VIB-UGent). “These cells form a smart, dynamic gate at a location we hadn’t fully appreciated. It’s exciting because it not only answers a fundamental anatomical question but also gives us a new target for understanding brain disease.”

A dynamic barrier vulnerable to disease

The team’s work shows that this barrier is not static. Under healthy conditions, it effectively limits the movement of even small molecules from the choroid plexus’ blood-rich core into the surrounding cerebrospinal fluid and brain tissue. However, during systemic inflammation, such as that caused by a severe infection, the barrier becomes compromised. ​

“We see that the base barrier cells become vulnerable during inflammation, potentially allowing harmful substances and cells to enter the central nervous system,” explains Dr. Daan Verhaege, who completed his PhD in the Vandenbroucke lab. ​
Left to right: Daan Verhaege, Roos Vandenbroucke, Clint De Nolf, Griet Van Imschoot, Pieter Dujardin, Lore Van Acker, Jonas Castelein, Lien Van Hoecke

The base barrier cells emerge early in development and are maintained throughout life. Importantly, the researchers confirmed that these cells are present not only in mouse brains but also in human brains, making the findings highly relevant to human health and disease. ​

This discovery opens new avenues for investigating neurological conditions and neuroinflammation, and may lead to novel therapeutic strategies aimed at strengthening this gatekeeper barrier.


Publication ​

Base barrier cells provide compartmentalization of choroid plexus, brain and CSF. Verhaege et al., Nature Neuroscience 2026

Funding

This work was funded by the Research Foundation Flanders (FWO) and the Baillet Latour Grant for Medical Research.

Special thanks to the VIB Bioimaging Core, VIB Flow Core and VIB Single Cell Core for training and support, and to VIB Tech Watch for early access grants.


Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be